Clinical Research Directory
Browse clinical research sites, groups, and studies.
SA030 Injection in Healthy Participants
Sponsor: Suzhou Siran Biotechnology Co.,Ltd.
Summary
This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses of SA030 injection in healthy participants. The planned dose levels include 100 mg, 200 mg, and 400 mg, with 8 eligible participants enrolled in each dose group. All participants receive a single administration of the study drug on Day 1 (D1). In each dose group, the first 2 participants are enrolled as sentinel participants and randomized at a 1:1 ratio to receive either SA030 injection or placebo. After a 5-day safety observation period and favorable safety assessment by the investigator, the remaining 6 participants in the group will be enrolled and randomized at a 5:1 ratio to receive SA030 injection or placebo. For dose escalation, at least 6 out of 8 participants in each dose group must complete the 14-day safety observation period (up to Day 15 \[D15\]). Subsequent dose escalation to the next higher dose level can only be initiated after safety review and approval by the Safety Review Committee (SRC).
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of SA030 Injection in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2026-10-16
Completion Date
2027-10-31
Last Updated
2026-11-13
Healthy Volunteers
Yes
Conditions
Interventions
Experimental: 100mg
Single subcutaneous injection of SA030 injection at a dose of 100 mg, one-time administration on Day 1.
Experimental: 200mg
Single subcutaneous injection of SA030 injection at a dose of 200 mg, one-time administration on Day 1.
Experimental: 400mg
Single subcutaneous injection of SA030 injection at a dose of 400 mg, one-time administration on Day 1.
Placebo
Single subcutaneous injection of placebo, one-time administration.
Locations (1)
The First Bethune Hospital of Jilin University
Changchun, Jilin, China